Syndromic Testing at Scale: What UK Laboratories Need to Weigh Before the 2026 Winter Respiratory Surge

As the 2026 winter respiratory season approaches, many UK laboratories are confronting a familiar problem in an unfamiliar form. The single-target PCR swab is no longer the whole story. Multiplex respiratory panels - assays that test for several viruses and, in some cases, atypical bacteria from one sample - are moving from specialist virology centres into routine NHS workflows. The appeal is obvious: faster syndromic answers, better cohorting and more rational use of antivirals and antibiotics. The operational reality is more demanding.

The science is not the hard part

Multiplex PCR works by running several primer and probe sets in parallel, often with fluorescent channels or melt-curve analysis, so that one specimen can yield a profile of influenza A and B, respiratory syncytial virus, SARS-CoV-2, adenovirus, human metapneumovirus, rhinovirus and enterovirus. Some panels add atypical bacterial targets. Sample-to-answer cartridges have compressed the hands-on time, while random-access platforms promise results closer to the patient.

The technical elegance can obscure a basic point: a result is not a diagnosis. Detection of nucleic acid does not always mean active disease, particularly where a pathogen is carried asymptomatically or persists after infection. A paediatric respiratory panel that returns rhinovirus in a wheezing child may be informative, but it may also be incidental. UK laboratories therefore need to ask not only whether a panel performs well analytically, but whether its results change clinical decisions in the local population.

Capacity is a pathway problem

Much of the UK debate about multiplex testing focuses on laboratory capacity, and rightly so. NHS pathology services have been consolidating into larger hubs, with smaller sites and near-patient settings feeding into them. A cartridge that produces a result in 45 minutes is not necessarily faster if the sample waits three hours for transport, or if the result sits unactioned in a queue.

Accreditation adds another layer. Laboratories working to ISO 15189 and assessed by UKAS must verify assays for their own use, even when a manufacturer supplies extensive validation data. For a multiplex panel, that means checking limit of detection, inclusivity and cross-reactivity across multiple targets, as well as interfering substances and specimen types. The workload multiplies with the target list. A laboratory that adds six targets to its menu is not simply adding six tests; it is adding six interpretive conversations.

Near-patient testing in emergency departments and acute medical units can ease pressure, but it shifts governance rather than removing it. Who performs the test, who reviews the result, how is the device maintained and how are results recorded in the patient record? These are adoption questions, not just procurement questions.

Stewardship needs action, not just data

One of the strongest arguments for syndromic respiratory testing is antimicrobial stewardship. A rapid influenza or RSV result can help clinicians stop unnecessary antibiotics, target antivirals and cohort patients more appropriately. During winter, when bed pressures are intense, that matters.

But stewardship dashboards are only as good as the data model beneath them. A dashboard that displays positivity rates without linking to prescribing, admission decisions or length of stay is a surveillance tool, not a stewardship tool. UK teams should ask how results will flow into laboratory information management systems and electronic patient records, whether coding uses SNOMED CT and whether messaging follows HL7 or FHIR standards. Bespoke interfaces are possible, but they are rarely cheap and often fragile.

Alert fatigue is a related risk. If every positive respiratory result triggers the same notification, clinical teams will learn to ignore it. The useful question is which results require a same-day action: cohorting, isolation, antiviral review or antibiotic time-out. The UK Health Security Agency's surveillance work and local epidemiology should inform that judgement, but the final design must fit the trust's own workflow.

What UK professionals should ask before adopting a panel

• What is the intended use and population, and has the target list been justified against local epidemiology and clinical need?
• What is the performance against a comparator, including for low-prevalence targets where positive predictive value falls?
• What clinical decision changes, and has clinical utility been demonstrated in an NHS setting rather than inferred from analytical sensitivity?
• What is the end-to-end turnaround time, from collection to result reviewed and acted upon?
• How will results integrate with the LIMS, electronic patient record and stewardship reporting without bespoke fixes?
• What is the cost per actionable result, including staff time, quality control, consumables, maintenance and waste?
• What is the accreditation and MHRA/UKCA position, and who owns local verification and ongoing competency assessment?
• What happens if supply fails in January, and is there a validated contingency pathway?

Multiplex respiratory testing is not simply a bigger swab. It is a pathway intervention. The UK laboratories that adopt it well will be those that treat validation, integration and stewardship as part of the assay, not as afterthoughts. The science can deliver a richer signal; the health system still has to decide what to do with it.